Anixa Biosciences, Inc. announced the formation of its Breast Cancer Clinical Advisory Board comprising preeminent experts across the breast cancer research and clinical development fields. This represents another milestone as the Company prepares for the next steps in advancing its breast cancer vaccine. The Anixa Biosciences Breast Cancer Clinical Advisory Board is comprised of the following members: Arnold Baskies, MD, FACS, is a specialist in surgical oncology and general surgery, affiliated with Virtua Health Systems. He is former Chairman of the National Board of Directors of the American Cancer Society and current Chair of the society's Global Cancer Control Advisory Council.

He is a member of the Global Breast Cancer Initiative, World Health Organization (WHO), and Director and Scientific Advisory Board Member of Anixa Biosciences. G. Thomas Budd, MD, FACP, is a specialist in breast cancer and the principal investigator of the Cleveland Clinic and Anixa partnered Phase 1 trial of the Breast Cancer Vaccine. He is Professor of Medicine in the Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Cancer Center, and Professor in the Department of Medicine, School of Medicine and member of the Immune Oncology Program, Case Comprehensive Cancer Center.

He is a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). Lisa H. Butterfield, Ph.D., is a tenured academician (UCLA and University of Pittsburgh) and former President of the Society of Immunotherapy of Cancer (SITC). She is an Adjunct Professor of Microbiology and Immunology at UCSF, a member of the UCSF Helen Diller Family Comprehensive Cancer Center, Cancer Immunotherapy, and core faculty at the Herbert Perkins Cellular Therapy and Transfusion Medicine Fellowship.

She is a member of the AACR Cancer Immunology Working Group Steering Committee, and a member and Chair of the U.S. Food and Drug Administration (FDA) Cellular, Tissues and Gene Therapies Advisory Committee. Brian Czerniecki, MD, Ph.D., is the Chair and Senior Member in the Moffitt Cancer Center Department of Breast Oncology and a renowned surgeon and physician scientist investigating the development of vaccines for the prevention of breast cancer and other solid tumors. He is recognized nationally for his contribution to the development of sentinel lymph node mapping.

He has published over 100 scientific articles and is the recipient of numerous grants for his research. Brian Leyland-Jones, MBBS, MD, Ph.D., FACP, FRCPC, is a pre-eminent clinical trialist in oncology and the recipient of numerous awards. He is the Chief Medical Officer of AIM-HI Accelerator Fund, OTraces, and the N OF 1 Mission.

In addition, he is a Scientific Advisory Board Member of the National Foundation for Cancer Research and NED Biosystems, Inc. He is the CSO of The Darwin Foundation, collectively devoted to the implementation of prevention and cure of malignancy globally, and Director Emeritus for the WIN (Worldwide Innovative Networking in personalized cancer medicine) Consortium. Hope Rugo, MD, FASCO, is a leader and specialist in breast cancer research and recipient of numerous awards. She is Professor, Department of Medicine (Hematology/Oncology), and Director, Breast Oncology and Clinical Trials Education, at the UCSF Helen Diller Family Comprehensive Cancer Center.

She is Co-chair of the Triple Negative Working Group, a member of the Translational Breast Cancer Research Consortium (TBCRC), Alliance Breast Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB), and a member of the American Society of Clinical Oncology (ASCO).